Myasthenia Gravis Panel 2

Order Name: ACETY BBM Test Number: 5500250 Revision Date: 01/01/2024

TEST NAME	METHODOLOGY	
Acetylcholine Receptor Binding Antibody	See Test Notes	11034-6
Acetylcholine Receptor Blocking Antibody	See Test Notes	11561-8
Acetylcholine Receptor Modulating Antibody	Flow cytometry	30192-9
SPECIMEN REQUIREMENTS		

Specimen	Specimen Volume (min)	Specimen Type	Specimen Container	Transport Environment
Preferred	2 mL (1.5)	Serum	Clot Activator SST	Refrigerated
Alternate 1	2 mL (1.5)	Serum	Clot Activator (Red Top, No-Gel)	Refrigerated
Instructions	Separate serum from cells ASAP or within 2 hours of collection Unacceptable Conditions: Contaminated, hemolyzed, or severely lipemic specimens.			

Stability After separation from cells: Ambient: 2 hours; Refrigerated: 2 weeks; Frozen: 1 year (avoid repeated freeze/thaw cycles)

GENERAL INFORMATION		
Testing Schedule	Sun-Sat	
Expected TAT	4-6 Days	
Clinical Use	Myastenia Gravis is a neurological disorder characterized by a decrease in acetylcholine receptors. Patients exhibit skeletal muscle weakness and fatigability. Approximately 80% of patients with Myastenia Gravis, excluding ocular involvement only, have detectable acetylcholine receptor antibody.	
CPT Code(s)	86041, 86042, 86043	
Lab Section	Reference Lab	